These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36895852)

  • 1. Clinical outcomes of volume of disease on patients receiving enzalutamide
    Nuzzo PV; Ravera F; Saieva C; Zanardi E; Fotia G; Malgeri A; Rossetti S; Valença LB; Oliveira TM; Vauchier C; Pereira Mestre R; Modesti M; Patrikidou A; Pignata S; Procopio G; Fornarini G; De Giorgi U; Russo A; Francini E
    Ther Adv Med Oncol; 2023; 15():17588359231156147. PubMed ID: 36895852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
    Nuzzo PV; Pederzoli F; Saieva C; Zanardi E; Fotia G; Malgeri A; Rossetti S; Valenca Bueno L; Andrade LMQS; Patrikidou A; Mestre RP; Modesti M; Pignata S; Procopio G; Fornarini G; De Giorgi U; Russo A; Francini E;
    J Transl Med; 2023 Feb; 21(1):75. PubMed ID: 36737752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
    Fotia G; Saieva C; Lee-Ying R; Patrikidou A; Nuzzo PV; Zanardi E; Rossetti S; Davidsohn M; Eid M; El Zarif T; McClure H; Spinelli GP; Damassi A; Murianni V; Vauchier C; Oliveira TM; Malgeri A; Modesti M; Mestre RP; Valenca L; Ravi P; Santini D; Pignata S; De Giorgi U; Sweeney C; Heng D; Procopio G; Russo A; Francini E;
    Clin Genitourin Cancer; 2024 Oct; 22(5):102185. PubMed ID: 39217072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
    Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
    J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
    Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
    Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
    Bjartell A; Costa L; Kramer G; Zurawski B; Galli L; Werbrouck P; Ecke T; Parikh O; Bennamoun M; Garcia Freire C; Peer A; Ljungberg B; Cicin I; Smith E; Lukac M; Wapenaar R; Chowdhury S
    Eur Urol Open Sci; 2022 Nov; 45():12-22. PubMed ID: 36353661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study.
    Bahl A; Sodatonou H; Snjider R; Chilelli A; Pranzo A; Martins K; Merseburger A; Rozario N; Crawley D
    World J Urol; 2024 Oct; 42(1):584. PubMed ID: 39422767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
    JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
    Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
    Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Pilon D; Queener M; Lefebvre P; Ellis LA
    J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
    Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M
    Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).
    Shore ND; Saltzstein D; Sieber P; Mehlhaff B; Gervasi L; Phillips J; Wong YN; Pei H; McGowan T
    Clin Genitourin Cancer; 2019 Dec; 17(6):457-463.e6. PubMed ID: 31473120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH
    Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.